<DOC>
	<DOCNO>NCT00585143</DOCNO>
	<brief_summary>Safety Study Evaluate Effects Mild Moderate Renal Impairment Pharmacokinetics ABT-335 Rosuvastatin When Administered Concomitantly</brief_summary>
	<brief_title>Safety Study Evaluate Effects Mild Moderate Renal Impairment Pharmacokinetics ABT-335 Rosuvastatin When Administered Concomitantly</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Inclusion Criteria Body Mass Index ( BMI ) 19 33 , inclusive Either normal kidney function , mild moderate kidney impairment Exclusion Criteria Use medication , vitamin and/or herbal supplement within 2 week prior study drug administration , except require management renal disease . History epilepsy , clinically significant cardiac , respiratory , renal , hepatic , gastrointestinal , hematologic psychiatric disease disorder , uncontrolled medical illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Dyslipidemia</keyword>
</DOC>